Usage Examples
- We cannot file the MAA until the QPPV is appointed and named in the PSMF.
- Our QPPV is contracted from a vendor, but the accountability still sits with us as MAH.
- Route that urgent authority request to the QPPV - they are the 24-hour contact point, not the affiliate.
What is Qualified Person for Pharmacovigilance (QPPV)?
Qualified Person for Pharmacovigilance (QPPV) is the single named individual, resident in the EU/EEA, whom a marketing authorisation holder must have permanently and continuously at its disposal to establish and maintain its EU pharmacovigilance system.
The QPPV exists because a pharmacovigilance system spread across affiliates, vendors, and case databases has no natural point of accountability, and an authority chasing an emerging safety signal cannot interrogate a committee. EU law therefore forces a marketing authorisation holder to put one appropriately qualified natural person, inside the Union, permanently and continuously at its disposal and answerable for that system.
The QPPV covers the establishment and maintenance of the holder's EU pharmacovigilance system: oversight of product safety profiles, authority over the content of risk management plans, input into regulatory action on emerging safety concerns, and the correctness and completeness of data submitted to authorities. The QPPV does not absorb the marketing authorisation holder's own legal responsibility, and the role is defined for the EU system, not a global title other regions recognise.
The QPPV is operationalised through three documents an inspector will ask for: the pharmacovigilance system master file, a job description defining the duties, and an organisational chart placing the role among managerial and supervisory staff. Each pharmacovigilance system has only one QPPV, who serves as the 24-hour contact point for national authorities, EMA, and inspections.
Not to be confused with
- Pharmacovigilance system master file (PSMF)
- the PSMF is the document that describes the system; the QPPV is the person accountable for it. Information relating to the QPPV sits inside the PSMF, and the QPPV must have access to it and authority over it.
- National pharmacovigilance contact person
- a Member State may request the nomination of a contact person at national level who reports to the QPPV on pharmacovigilance tasks. That role is national and subordinate; the QPPV owns the whole EU system, though one person may hold both.
- Deputy or back-up QPPV
- back-up procedures for QPPV absence are mandatory, but the back-up is not a second QPPV. Each pharmacovigilance system can have only one QPPV, and the back-up is reached through the QPPV's own contact details.
- Qualified Person (QP)
- the QP under EU GMP certifies batch release for manufactured product. Different legal basis, different competency, different accountability. The shared word "qualified" is the only overlap, and it regularly produces mis-scoped job specs.
These are the obligations that sit on the marketing authorisation holder, not on the individual alone.
What you must do
- 1Have permanently and continuously at your disposal an appropriately qualified person responsible for pharmacovigilance in the EUDirective 2001/83/EC Art 104(3)(a)
- 2Appoint a QPPV who resides and operates in the EU, or in Norway, Iceland or Liechtenstein under EEA agreements, and keep back-up procedures in place for their absenceDirective 2001/83/EC Art 104(3) last paragraph
- 3Ensure the QPPV has acquired adequate theoretical and practical knowledge, and where they have not completed basic medical training under Article 24 of Directive 2005/36/EC, ensure documented assistance from a medically trained personCommission Implementing Regulation (EU) No 520/2012 Art 10(1)
- 4Define the QPPV's duties in a job description and their hierarchical relationship in an organisational chart alongside other managerial and supervisory staffCommission Implementing Regulation (EU) No 520/2012 Art 10(2)
- 5Make the QPPV the single pharmacovigilance contact point for competent authorities and the Agency on a 24-hour basis, and the contact point for pharmacovigilance inspectionsGVP Module I, section I.C.1.3
Common mistakes
Naming a safety head who lives outside the EU/EEA
residence and operation inside the EU (or Norway, Iceland, Liechtenstein) is a condition of the appointment, not a preference. A US- or UK-resident QPPV invalidates the appointment on its face, and the finding goes to the legality of the entire pharmacovigilance system rather than to a single process.
Appointing a QPPV on paper without authority or information flow
the holder must ensure the QPPV has sufficient authority to influence the quality system and pharmacovigilance activities, plus access to the PSMF and to emerging safety information. Inspectors test this by asking the QPPV to demonstrate oversight; a QPPV who hears about signals late, or cannot trigger an audit, fails that test.
Treating outsourcing as a transfer of responsibility
subcontracting the QPPV role to a service provider is permitted, but ultimate responsibility for all pharmacovigilance tasks and for the quality and integrity of the system always remains with the marketing authorisation holder. Small companies buy the role, then discover at inspection that the accountability never left.
When This Matters
- We cannot file the MAA until the QPPV is appointed and named in the PSMF.
- Our QPPV is contracted from a vendor, but the accountability still sits with us as MAH.
- Route that urgent authority request to the QPPV - they are the 24-hour contact point, not the affiliate.
Frequently Asked Questions
Yes. The QPPV must reside and operate in the EU, and under European Economic Area agreements may instead reside and operate in Norway, Iceland or Liechtenstein. A safety head based in the US, Switzerland or the UK cannot hold the role, regardless of seniority or qualifications.
Related Use Cases
Related Regulatory Intelligence
Related Actions
- Lifecycle Management
Track every sequence operation, amendment, and supplement across the product lifecycle.
- Regulatory Intelligence
Monitor FDA, EMA, ICH, and Health Canada guidance changes across active programs.
- Regulatory Affairs Software
Plan, validate, and execute active submissions in one workspace.
Sources & References
- EMA - Guideline on good pharmacovigilance practices (GVP) Module I: Pharmacovigilance systems and their quality systems
- EMA - Good pharmacovigilance practices (GVP)
- Directive 2001/83/EC on the Community code relating to medicinal products for human use
- Commission Implementing Regulation (EU) No 520/2012 on the performance of pharmacovigilance activities
